2017—2020年天津市10家医院心血管疾病患者住院期间抗血小板药应用分析

Analysis on Application of Antiplatelet Drugs on Patients with Cardiovascular Disease During Hospitalization in 10 Hospitals in Tianjin from 2017 to 2020

目的:了解天津市心血管疾病患者住院期间抗血小板药使用情况,以期为规范合理用药提供依据。方法:以2017—2020年天津市10家医院心血管科住院患者为研究对象,应用Epidata软件进行数据录入,应用SPSS 26.0软件进行统计分析。结果:共纳入1178例患者,其中心绞痛患者499例(占42.4%),急性心肌梗死患者158例(占13.4%),冠心病患者390例(占33.1%),其他类型疾病患者131例(占11.1%);抗血小板药各药品选用率由高至低依次为阿司匹林、氯吡格雷、替格瑞洛、替罗非班和西洛他唑;负荷剂量联合用药方式主要为阿司匹林与氯吡格雷联合应用,但负荷剂量应用率较低;维持剂量联合用药方式主要为阿司匹林与氯吡格雷联合应用;不同疾病用药行为特点存在差异,同一疾病用药行为特点亦存在不一致性。结论:天津市心血管疾病住院患者在抗血小板药的品种选用、负荷剂量、维持剂量和联合应用方式上存在用药行为差异,科学规范的治疗策略仍需大样本真实世界研究加以确证。

OBJECTIVE:To investigate the application of antiplatelet drugs on patients with cardiovascular disease during hospitalization in Tianjin,so as to provide references for standardizing rational drug application.METHODS:Inpatients in department of cardiovascular in 10 hospitals in Tianjin from 2017 to 2020 were set as subjects,Epidata software was used to conduct data input,SPSS 26.0 was used for data collecting and analyzing.RESULTS:Totally1178 patients were involved,of which 499 patients(42.4%)with angina pectoris,158 patients(13.4%)with acute myocardial infarction,390 patients(33.1%)with coronary heart disease,131 patients(11.1%)with other types of diseases;the selection rate of antiplatelet drugs from high to low were respectively aspirin,clopidogrel,ticagrelor,tirofiban and cilostazol;the administration route of loading dose combination were mainly with aspirin and clopidogrel,but the loading dose application rate was low;the administration route of maintenance dose combination were mainly with aspirin and clopidogrel;there were differences in the characteristics of the medication behavior of different diseases,while there were also inconsistencies in characteristics of the medication behavior of same disease.CONCLUSIONS:There are differences in the medication behavior of inpatients with cardiovascular diseases in Tianjin in the drug selection,loading dose,maintenance dose and drug combination of antiplatelet drugs,the scientific and standardized treatment strategy still needs to be confirmed by large sample of real-world studies.